© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 13, 990-1000,
July 2, 2003
© 2003 Oxford University Press
ARTICLE |
Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer
Affiliations of authors: S. R. Denmeade, S. Janssen, S. R. Khan, E. S. Garrett, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; C. M. Jakobsen, S. B. Christensen, Department of Medicinal Chemistry, Pharmaceutical University of Denmark, Copenhagen; H. Lilja, Department of Clinical Chemistry, Lund University, Malmö, Sweden; J. T. Isaacs, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and The James Buchanan Brady Urologic Institute, Departmenty of Urology, The Johns Hopkins School of Medicine.
Correspondence to: Samuel R. Denmeade, M.D., The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Bldg., 1650 Orleans St., Baltimore, MD 21231 (e-mail: denmesa{at}jhmi.edu).
Background: Standard anti-proliferative chemotherapy is relatively ineffective against slowly proliferating androgen-independent prostate cancer cells within metastatic sites. In contrast, the lipophilic cytotoxin thapsigargin, which causes apoptosis by disrupting intracellular free Ca2+ levels, is effective against both proliferative and quiescent (i.e., G0-arrested) cells. However, thapsigargin’s mechanism of action indicates that it is unlikely to be selective for cancer cells or prostate cells. Methods: We coupled a chemically modified form of thapsigargin, L12ADT, to a peptide carrier that is a substrate for the prostate-specific antigen (PSA) protease to produce a soluble, cell-impermeant latent prodrug that is specifically activated extracellularly within metastatic prostate cancer sites by PSA. We analyzed the kinetics of PSA hydrolysis of the prodrug, the in vitro cytoxicity of the prodrug against PSA-producing LNCaP human prostate cancer and PSA non-producing HCT-116 human colon cancer cells, and the in vivo pharmacokinetics of the prodrug in mice. We also analyzed antitumor efficacy of the prodrug in nude mice xenograft models of prostate cancer (using LNCaP cells) and renal carcinoma (using human SN12C cells). Results: The L12ADT peptide prodrug was hydrolyzed efficiently by PSA, was selectively toxic to PSA-producing prostate cancer cells in vitro, and was stable in human plasma. A single dose of 7 mg/kg resulted in a peak serum prodrug concentration of 15.4 ± 1.1 µM and a half-life of approximately 2.8 hours. Over 24 hours, less than 0.5% of free L12ADT was observed in plasma. Levels of prodrug and liberated L12ADT in prostate cancer xenograft tumors were approximately eightfold and sixfold, respectively, higher than the in vitro LD50s. Prostate cancer xenograft tumors in mice treated with prodrug by intravenous administration were growth-inhibited without substantial host toxicity. Continuous subcutaneous prodrug administration in mice produced complete growth inhibition of established PSA-producing prostate cancer xenograft tumors but had no effect on PSA non-producing renal carcinoma xenograft tumors. Conclusion: Further development of PSA-activated thapsigargin prodrugs as therapy for metastatic prostate cancer is warranted.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. M. LeBeau, W. N. Brennen, S. Aggarwal, and S. R. Denmeade Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin Mol. Cancer Ther., May 1, 2009; 8(5): 1378 - 1386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Vander Griend, L. Antony, S. L. Dalrymple, Y. Xu, S. B. Christensen, S. R. Denmeade, and J. T. Isaacs Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells Mol. Cancer Ther., May 1, 2009; 8(5): 1340 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Fels, J. Ye, A. T. Segan, S. J. Kridel, M. Spiotto, M. Olson, A. C. Koong, and C. Koumenis Preferential Cytotoxicity of Bortezomib toward Hypoxic Tumor Cells via Overactivation of Endoplasmic Reticulum Stress Pathways Cancer Res., November 15, 2008; 68(22): 9323 - 9330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dagvadorj, R. A. Kirken, B. Leiby, J. Karras, and M. T. Nevalainen Transcription Factor Signal Transducer and Activator of Transcription 5 Promotes Growth of Human Prostate Cancer Cells In vivo Clin. Cancer Res., March 1, 2008; 14(5): 1317 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Chandran, A. Nan, D. M. Rosen, H. Ghandehari, and S. R. Denmeade A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer Mol. Cancer Ther., November 1, 2007; 6(11): 2928 - 2937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Williams, R. F. Merchant, E. Garrett-Mayer, J. T. Isaacs, J. T. Buckley, and S. R. Denmeade A Prostate-Specific Antigen-Activated Channel-Forming Toxin as Therapy for Prostatic Disease J Natl Cancer Inst, March 7, 2007; 99(5): 376 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. R. Sastry, Y. Karpova, and G. Kulik Epidermal Growth Factor Protects Prostate Cancer Cells from Apoptosis by Inducing BAD Phosphorylation via Redundant Signaling Pathways J. Biol. Chem., September 15, 2006; 281(37): 27367 - 27377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Janssen, C. M. Jakobsen, D. M. Rosen, R. M. Ricklis, U. Reineke, S. B. Christensen, H. Lilja, and S. R. Denmeade Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer Mol. Cancer Ther., November 1, 2004; 3(11): 1439 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Jensen, T. L. Andresen, J. Davidsen, P. Hoyrup, S. D. Shnyder, M. C. Bibby, J. H. Gill, and K. Jorgensen Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids Mol. Cancer Ther., November 1, 2004; 3(11): 1451 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamaguchi and H.-G. Wang CHOP Is Involved in Endoplasmic Reticulum Stress-induced Apoptosis by Enhancing DR5 Expression in Human Carcinoma Cells J. Biol. Chem., October 29, 2004; 279(44): 45495 - 45502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Uzgare and J. T. Isaacs Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells Cancer Res., September 1, 2004; 64(17): 6190 - 6199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Ley, A. Antonello, E. P. Balskus, D. T. Booth, S. B. Christensen, E. Cleator, H. Gold, K. Hogenauer, U. Hunger, R. M. Myers, et al. Natural Product Synthesis Special Feature: Synthesis of the thapsigargins PNAS, August 17, 2004; 101(33): 12073 - 12078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Xu, H. Ma, G. Inesi, M. K. Al-Shawi, and C. Toyoshima Specific Structural Requirements for the Inhibitory Effect of Thapsigargin on the Ca2+ ATPase SERCA J. Biol. Chem., April 23, 2004; 279(17): 17973 - 17979. [Abstract] [Full Text] [PDF]
|
|